David S Wilson

Introduction: David S Wilson is a notable inventor based in Frazer, Pennsylvania. He has made significant contributions to the field of cancer treatment through his innovative approaches and patented technologies. With a total of six patents to his name, Wilson's work focuses on combination therapies that target tumor cells effectively.

Latest Patents: Among his latest patents is the "Anti-CD47 combination therapy," which provides a novel approach for treating tumors. This invention includes a polypeptide construct linked to an antibody that targets specific antigens on tumor cells, along with a CD47 antagonist that inhibits the interaction with the SIRPα receptor. Another significant patent is the "Combination of lenalidomide and polypeptide construct," which outlines methods for treating various cancers, including B-cell lymphoma and multiple myeloma, by administering an anti-CD38 antibody-attenuated human IFN alpha-2b construct alongside lenalidomide or pomalidomide.

Career Highlights: David has worked with prominent companies in the pharmaceutical industry, including Teva Pharmaceuticals Australia Pty Ltd and Teva Pharmaceuticals Pty Ltd. His experience in these organizations has contributed to his expertise in developing innovative cancer therapies.

Collaborations: Throughout his career, David has collaborated with talented individuals such as Sarah Lee Pogue and Anthony Gerard Doyle. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking

This text is generated by artificial intelligence and may not be accurate.